Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Beta-caryophyllene is a dietary cannabinoid found in many essential oils, such as clove, black pepper, and cannabis. Recent scientific studies have investigated its potential to reduce the side effects of chemotherapy. Preclinical research, primarily in animal models, has demonstrated that beta-caryophyllene can exert anti-inflammatory, analgesic, and gastroprotective effects, which are relevant to the side effects often experienced during chemotherapy (e.g., pain, inflammation, and gastrointestinal disturbances). For example, studies have shown that beta-caryophyllene activates the CB2 cannabinoid receptor, which is known to modulate immune responses and inflammation without eliciting the psychoactive effects associated with CB1 receptor activation.

Some animal studies have reported that beta-caryophyllene may help protect against chemotherapy-induced mucositis and oxidative stress, as well as enhance the efficacy of certain chemotherapeutic agents while reducing their toxicity. However, clinical evidence in humans is currently sparse, and most claims are extrapolated from preclinical research. As a result, while there is a scientific rationale and preliminary evidence supporting its potential benefits, these findings await robust confirmation in well-designed human trials.

In summary, beta-caryophyllene is being actively researched for its ability to mitigate chemotherapy side effects, but the current evidence base is limited and primarily preclinical. Thus, its use is not yet strongly supported by high-quality clinical data. Consumers and clinicians should await further studies before considering it a validated adjunct for chemotherapy support.

More about beta caryophyllene
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by beta caryophyllene

Products containing beta caryophyllene